INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To assess the prognostic value of LoRRca ektacytometry as biomarker providing information of SCD/RADs patients severity
Timeframe: Through study completion, an average of 2 year